Targeting the Nociceptin/Orphanin FQ Receptor for Scleroderma Therapy
Technical Report,10 Nov 2014,09 Nov 2015
Palo Alto Veterans Institute for Research Palo Alto United States
Pagination or Media Count:
Scleroderma is a debilitating disease of the connective tissue that affects about 75,000100,000 individuals in the United States and accounts for an estimated 400 million in total annual medical costs. There is no treatment that stops or cures scleroderma novel therapies are therefore urgently needed. The overall objective of this proposal is to demonstrate that small molecule compounds that target receptor-ligand pair NOP receptorNociceptinOrphanin FQ can limit the damage and malfunctions that occur in the immune system and in blood vessels during scleroderma. We anticipate that our approach will demonstrate that a single drug can limit inflammation, heal blood vessel damage, and increase blood flow.